TY  - JOUR
T1  - A curious case of β-blockers in chronic obstructive pulmonary disease
AU  - Sin DD, Man S
Y1  - 2010/05/24
N1  - 10.1001/archinternmed.2010.97
JO  - Archives of Internal Medicine
SP  - 849
EP  - 850
VL  - 170
IS  - 10
N2  - 
β-Blockers are highly efficacious in the treatment of congestive heart failure and ischemic coronary syndromes and can reduce the total mortality of patients with these disorders by 30% to 40%.1 However, their use is frequently withheld inpatients who have coexisting chronic obstructive pulmonary disease (COPD) because clinicians fear that β-blockers will provoke bronchospasm and induce respiratory failure in these patients. Not surprisingly, large epidemiological studies have shown that fewer than one-third of patients with COPD receive β-blockers after an acute coronary event2 despite compelling data that they prolong life and improve health outcomes in such patients.1

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2010.97
UR  - http://dx.doi.org/10.1001/archinternmed.2010.97
ER  -